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Natural killer (NK) cells are lymphocytes of the innate immune system that secrete
cytokines upon activation and mediate the killing of tumor cells and virus-infected cells,
especially those that escape the adaptive T cell response caused by the down regula-
tion of MHC-I. The induction of cytotoxicity requires that NK cells contact target cells
through adhesion receptors, and initiate activation signaling leading to increased adhesion
and accumulation of F-actin at the NK cell cytotoxic synapse. Concurrently, lytic granules
undergo minus-end directed movement and accumulate at the microtubule-organizing cen-
ter through the interaction with microtubule motor proteins, followed by polarization of
the lethal cargo toward the target cell. Ultimately, myosin-dependent movement of the
lytic granules toward the NK cell plasma membrane through F-actin channels, along with
soluble N -ethylmaleimide-sensitive factor attachment protein receptor-dependent fusion,
promotes the release of the lytic granule contents into the cleft between the NK cell and
target cell resulting in target cell killing. Herein, we will discuss several disease-causing
mutations in primary immunodeficiency syndromes and how they impact NK cell-mediated
killing by disrupting distinct steps of this tightly regulated process.
Keywords: NK cells, primary immunodeficiency, NK cell cytotoxicity, cytotoxic lymphocytes, cytotoxic synapse,
lytic granules
INTRODUCTION
Natural killer (NK) cells comprise 5–15% of human peripheral
blood lymphocytes and play an important role in the clear-
ance of virally infected cells, as well as the elimination of cancer
cells (1, 2). The main population of NK cells differentiates from
hematopoietic stem cells in the bone marrow, and fully matures
as CD56+CD16+ NK cells in secondary lymphoid organs (3).
While several recent studies have elegantly demonstrated the pres-
ence of a memory immune response in NK cells, previously only
attributed to T and B cells of the adaptive immune system (4,
5), NK cells are generally recognized as innate immune cells by
the fact that their receptors do not undergo DNA rearrangement
processes. Instead NK cells express various germline-encoded acti-
vating and inhibitory NK receptors on their cell surface (6–8).
Integrated signaling from both activating and inhibitory recep-
tors is thought to enable NK cells to distinguish healthy “self”
from infected or stressed unhealthy or “non-self” cells (9, 10).
Therefore, activation of NK cells can be achieved via the liga-
tion of a number of activating receptors with their corresponding
ligand on the target cell (natural cytotoxicity). In addition, NK
cells are also able to detect antibody-coated targets through the
low affinity Fc receptor CD16 (FcγRIIIA) and thereby mediate
antibody-dependent cellular cytotoxicity (ADCC) (11, 12). The
main consequence of NK cell activation is the direct killing of
bound unhealthy target cells through the release of perforin and
granzymes from a preformed secretory lysosome known as the
lytic granule (13, 14). In addition, NK cells can affect the over-
all immune response through the secretion of chemokines and
cytokines (3, 15–18) as well as through direct interaction with
other immune cells (2, 5).
Research conducted over the past quarter of a century has
uncovered the process of NK cell development, identified and
demonstrated the function of activating and inhibitory receptors,
and provided a wealth of information regarding the signaling path-
ways that are linked to these receptors and the proteins that are
critical to the delivery of the lethal cargo to the target cell. Signifi-
cantly, the study of human primary immunodeficiency syndromes
(PIDs) has provided invaluable knowledge and insight regarding
the role of NK cells in the immune system, and in addition has
also resulted in the identification of genes whose protein prod-
ucts regulate distinct steps that are critical to the development of
cellular cytotoxicity by this population of innate immune cells.
Among the PIDs, several NK cell deficiencies have been identified
including rare isolated NK cell deficiencies, where there is total
absence or very low number of NK cells in the peripheral blood,
which is known as classical natural killer cell deficiency (CNKD)
(19, 20). MCM4 and GATA2 are the only two genes identified thus
far in which mutations are linked to CNKD, however there remain
several cases of CNKD where the underlying genetic cause has
not been identified (20). Clearly, sequencing of the genomes in
patients with CNKD, which are not caused by mutation of either
MCM4 or GATA2, will undoubtedly reveal other genes that play
an important role in NK cell development or survival.
The term NK cell deficiency does not just mean an absence
of NK cells in the immune system; it also includes the absence
of specific NK cell effector functions, like cytotoxicity, despite the
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presence of normal NK cell numbers. This has been termed func-
tional NK cell deficiency (FNKD) (19, 20). FNKDs have provided
us with very valuable insights into the roles of specific NK cell func-
tions in immunity as well as essential proteins required for NK cell
effector activities, when the responsible gene has been identified.
So far, the only known human genetic mutation leading to FNKD
is in the FCGR3A gene, which encodes CD16 (20, 21). Similar to
patients of CNKD, patients carrying homozygous missense muta-
tions in CD16 (L66H) showed susceptibility to human papilloma
virus (HPV) or herpesviridae members. In contrast to CKND,
these patients had normal numbers of NK cells, but unexpectedly
showed normal ADCC, whereas natural cytotoxicity was defective
(20). The fact that the altered amino acid found in these patients
is located outside of the immunoglobulin domain (Ig domain)
responsible for IgG binding (22) suggests why ADCC of NK cells
from the patients is normal. In addition, novel co-stimulatory roles
of CD16 mediated by the distal Ig domain of CD16 (23) provided
important insights that might explain why the patients’ NK cells
showed defective natural cytotoxicity.
Lastly, there are several additional human PIDs that demon-
strate defects in NK cell numbers and effector functions. Since
many immune cells other than NK cells are also affected, there
are additional complications and difficulties in understanding the
complex immunological roles of NK cells in these diseases. How-
ever, the identification of specific gene mutations has illuminated
molecular pathways that are important for NK cell development
and effector functions, which are also shared in other immune cell
types. In this review, we will specifically focus on PIDs where the
mutated gene products impact the intracellular pathways that reg-
ulate the development of NK cell-mediated cytotoxicity (Table 1).
For detailed discussions about human diseases involved in NK
cell development and differentiation, NK cell signaling, or other
NK cell effector functions, the reader is referred to other excellent
reviews on these topics (19–21, 24).
BIOGENESIS OF LYTIC GRANULES AND THEIR MATURATION
Cell-mediated killing by NK cells and cytotoxic T lymphocytes
(CTLs) is achieved by directed release of lytic granules toward
bound target cells. Lytic granules are dual-function organelles
that exhibit characteristics of a degradative lysosome, but can
also secrete granule constituents for cell-mediated killing and are
therefore often referred to as a secretory lysosome. This spe-
cialized organelle is mostly observed in hematopoietic lineage
cells, but it is also found in melanocytes that produce pigment
proteins called melanins (25, 26). Both secretory lysosomes and
conventional lysosomes are acidic organelles (pH 5.1–5.4), mor-
phologically similar, and contain proteins like acid hydrolases that
are required for their degradative function as well as receptor pro-
teins including members of the lysosomal-associated membrane
protein (LAMP) family. On the other hand, the main distinction
of secretory lysosomes from conventional lysosomes is that secre-
tory lysosomes undergo a regulated secretion process and they
contain additional contents that are cell-type-specific. In the case
of NK cells and CTLs, these specific secreted contents include per-
forin and granzymes, which are essential for cytotoxic activity.
On the other hand, the main secreted proteins of melanocytes
are melanins, which are pigments responsible for skin color. Cells
containing secretory lysosomes use common secretory machiner-
ies, but cell-type-specific secreted contents enable each cell type to
perform different effector functions. This is why human genetic
diseases such as Chediak–Higashi syndrome (CHS) and type 2
Hermansky–Pudlak syndrome (HPS), caused by impaired func-
tion of the secretory lysosome, are characterized not only by
severe immune deficiencies including defective cytotoxicity by NK
cells and CTLs but also by hypopigmentation due to defects in
melanosome formation and excessive bleeding due to the absence
of dense granules in platelets (26–28).
In contrast to CTLs, which need to be activated, the genes
encoding perforin and granzymes are constitutively transcribed
in NK cells thus allowing them to immediately kill an infected
or stressed cell upon initial contact and without the need for
additional gene expression (29, 30). Perforin is essential for NK
cell-mediated cytotoxicity, since it is the only molecule that delivers
apoptosis-inducing granzymes into the target cell. Perforin is ini-
tially synthesized as an inactive precursor in the ER and undergoes
multiple posttranslational modifications including proteolysis and
glycosylation during its transit to the Golgi and finally to the
lytic granule (31). However, the exact pathway that sorts per-
forin from the trans-Golgi network (TGN) into lytic granules
is unresolved. After arriving into lytic granules, perforin is fur-
ther processed by cathepsin L to develop into a mature form.
In the case of granzymes, five different granzymes, granzyme A,
B, H, K, and M, are expressed in human NK cells and CTLs.
They are synthesized as pro-enzymes and modified to have a
mannose-6-phosphate moiety in the cis-Golgi, which facilitates
their trafficking to the endosome by the mannose-6-phosphate
receptor (M6PR) before finally arriving into the lytic granule (32,
33). In lytic granules, granzymes are further processed into an
active form by various cathepsins (34–36). Granzymes are serine
proteases and each granzyme has different substrate specificity and
induces apoptosis in the target cell in both caspase-dependent and
caspase-independent manners (37, 38).
An important question to be asked is: How do cytotoxic lym-
phocytes protect themselves from these dangerous molecules?
Significantly, the activity of perforin is achieved by the membrane
attack complex/perforin (MACPF) domain, which has cytolytic
activity, and a C2 domain that enables binding to membrane in a
calcium-dependent manner (37, 39, 40). Importantly, the low level
of Ca2+ in lytic granules maintains perforin in an inactive confor-
mation. In addition, calreticulin, another component of the lytic
granule, inhibits perforin activity (41), and the acidic environment
of lytic granules provides protection to NK cells since the activity
of both perforin and granzymes are inhibited at this low pH. Fur-
thermore, the low pH environment favors association of serglycin,
a proteoglycan matrix found within lytic granules, with both per-
forin and granzymes. This interaction keeps both perforin and
granzymes in an inactive state until they are secreted into a neu-
tral pH environment (42). Interestingly, the mechanism by which
perforin facilitates the transport of granzymes into the target cell
is still unclear (37, 40). According to the prevailing model, perforin
is released into the cytotoxic synaptic cleft where it binds calcium,
oligomerizes on the target membrane, and forms pores. The high
concentration of calcium as well as the neutral pH at the inter-
face between NK cells and target cells relieves perforin from its
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Table 1 | Human primary immunodeficiency syndromes with defective NK cell cytotoxicity.
NK cytotoxicity
process
Disease Gene
mutated
Protein
affected
NK cell defects in cytotoxicity Rescued
by IL-2
Lytic granule
biogenesis
Familial hemophagocytic
lymphohistiocytosis type 2 (FHL2)
PFR1 Perforin Exocytosis of lytic granules is normal, but no
cytotoxicity is achieved due to absence of
pore-forming molecule
No
Papillon–Lefèvre syndrome (PLS) CTSC Cathepsin C Granzyme B in lytic granules is not fully
processed, causing defective cytotoxicity
Yes
Hermansky–Pudlak syndrome type
2 (HPS2)
AP3B1 β3A-subunit of
adaptor
protein 3
Enlarged lytic granules impaired movement
along microtubules? Less perforin in lytic
granules?
?
Chediak–Higashi syndrome (CHS) CHS1/LYST CHS1/LYST Enlarged lytic granules. Impaired exocytosis
of lytic granules (unknown cause)
?
Adhesion to target
cells
Leukocyte adhesion deficiencies
type 1 (LAD-I)
ITGB2 β2-subunit of
integrin (CD18)
Impaired adhesion to target cells. Impaired
polarization
Yes
Leukocyte adhesion deficiencies
type 3 (LAD-III)
FERMT3 Kindlin-3 Impaired adhesion. Impaired specific
activating receptor-mediated cytotoxicity, but
normal natural cytotoxicity
?
F-actin
rearrangement
Wiskott–Aldrich syndrome (WAS) WASP WASP Impaired adhesion to target cells. Impaired
reorganization of F-actin and integrins.
Impaired polarization of lytic granules.
Yes
WASP-interacting protein (WIP)
deficiency
WIPF1 WIP Reduced surface expression of some NK
activating receptors. No detectable WASP.
No
Dedicator of cytokinesis 8 (DOCK8)
deficiency
DOCK8 DOCK8 Impaired adhesion to target cells. Impaired
reorganization of F-actin and integrins.
Impaired polarization of lytic granules.
No
Polarization of lytic
granules toward CS
MYH9-related diseases (MYH9-RD) MYH9 Myosin IIA Impaired exocytosis of lytic granules ?
Fusion of lytic
granules into PM
Griscelli syndrome type 2 (GS2) RAB27A RAB27A Impaired exocytosis of lytic granules Yes
Familial hemophagocytic
lymphohistiocytosis type 3 (FHL3)
UNC13D Munc13-4 Impaired exocytosis of lytic granules No
Familial hemophagocytic
lymphohistiocytosis type 4 (FHL4)
STX11 Syntaxin-11 Impaired exocytosis of lytic granules Yes
Familial hemophagocytic
lymphohistiocytosis type 5 (FHL5)
STXBP2 Munc18-2 Impaired exocytosis of lytic granules Yes
?=Unknown or equivocal.
inhibited conformation and triggers its activity (40). It is assumed
that the established pore is large enough for granzymes to get into
target cells by simple diffusion (21, 37, 40). Last but not least, how
do NK cells prevent themselves from potential self-destruction
from released cytotoxic components? Cell surface expression of
cathepsin B has been suggested to provide protection of cytotoxic
lymphocytes by cleaving perforin (43). In addition, it was recently
shown that the surface expression of LAMP-1 (CD107a) also pro-
tects NK cells from degranulation-associated damage by inhibiting
binding of perforin to NK cells (44). Therefore, it seems there exist
multiple layers of protection at the final degranulation step that
ensure unidirectional cytotoxicity. In the following paragraphs, we
will focus our discussion on PIDs with impaired NK cell cytotoxi-
city caused by: (1) defects in the contents of lytic granules and (2)
impaired biogenesis and maturation of lytic granules.
PIDs AFFECTING CONTENTS OF LYTIC GRANULES
Familial hemophagocytic lymphohistiocytosis type 2
Familial hemophagocytic lymphohistiocytosis type 2 (FHL2) is an
autosomal recessive disorder comprising 13–58% of all FHL cases
and is caused by mutation of the PFR1 gene, which encodes per-
forin (45). Most of the mutations identified in FHL2 patients occur
within regions critical for perforin maturation, or impair proper
folding, oligomerization, or Ca2+-mediated membrane binding
(31, 46). Interestingly, each mutation can dramatically impact the
level of mature perforin, ranging from absent to normal. Addi-
tionally, the intrinsic activities of the mutated perforin correlate
with the age of FHL onset and the severity of the disease (47–
52). Significantly, the inability of the mutated perforin to form
pores on target cell membranes results in the absence of cytotoxic
function of NK cells from FHL2 patients. Perforin loss did not
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affect the level of other lytic granule components (granzymes and
cathepsins) or the steps leading to lytic granule polarization and
membrane fusion (45, 53). Therefore, the normal degranulation
(examined by surface expression of CD107) observed in NK cells
from FHL2 patients provides us an important criterion to distin-
guish FHL2 patients from FHL patients caused by mutation of
other genes (53). In many cases, FHL2 patients usually further
develop other diseases including leukemia, juvenile rheumatoid
arthritis, and macrophage activation syndrome (48, 54–61), sug-
gesting an important role for perforin and cytotoxic activity medi-
ated by NK cells and CD8+ T cells in limiting or preventing these
diseases. In addition, the non-redundant role of perforin activity
in cellular cytotoxicity suggests the intervention of perforin activ-
ity as a potential therapeutic target in human diseases caused by
abnormal cytotoxicity of cytotoxic lymphocytes (52).
Papillon–Lefèvre syndrome
Papillon–Lefèvre syndrome (PLS) is a rare autosomal recessive dis-
ease caused by mutation of the gene encoding cathepsin C, CTSC
(62–64). This disease is clinically characterized by palmoplantar
keratosis, early onset of severe periodontitis, and susceptibility
to viral infections. Cathepsin C is a lysosomal cysteine protease,
which is responsible for the processing of granzyme A and B (36,
65). Consequently, NK cells from PLS patients primarily contain
immature granzyme B, and hence, their NK cells show impaired
cytotoxic activity (34). Interestingly, the impaired processing of
granzyme B as well as the defective cytotoxicity could be restored
by treatment of interleukin-2 (IL-2), suggesting that an IL-2 sig-
naling pathway is able to process granzyme B in a cathepsin
C-independent manner (34, 66).
PIDs AFFECTING BIOGENESIS AND MATURATION OF LYTIC GRANULES
Hermansky–Pudlak syndrome type 2
Hermansky–Pudlak syndrome is an autosomal recessive disease
clinically characterized by oculocutaneous albinism and excessive
bleeding (67, 68). Among the currently identified nine different
types of HPS, Hermansky–Pudlak syndrome type 2 (HPS2) is
the only type known to cause immunodeficiency in addition to
other clinical symptoms (67, 69, 70). HPS2 is caused by muta-
tion of the AP3B1 gene that encodes the β3A-subunit of adaptor
protein 3 (AP3), which is part of a heterotetrameric protein com-
plex (67, 71). Mutations leading to the loss of the β3A-subunit
affect the stability of other subunits and thereby induce loss of
the entire complex (67). The AP3 complex mediates sorting of
integral membrane proteins from the endosome and TGN to the
lysosome and secretory lysosome (72, 73). Considering the ubiqui-
tous expression of AP3, it is very interesting to note that its absence
causes severe functional defects only in cells with secretory lyso-
somes, indicating that AP3 is required for the biogenesis of secre-
tory lysosomes and/or in sorting of secretory lysosome-specific
proteins.
In the case of melanocytes, the AP3 complex was shown to
be responsible for sorting of tyrosinase, a protein required for
melanin synthesis, into the melanosome (74). Additionally, AP3-
deficiency was shown to cause defective cytotoxicity of both NK
cells and CTLs (17, 75–77). While perforin levels in CTLs have
been reported to be within the normal range in some patients
with HPS2 (76), NK cells from two siblings with HPS2 showed
less intracellular perforin levels compared to NK cells from healthy
controls (75), suggesting that the defective NK cell-mediated cyto-
toxicity observed in these patients is at least partially a result of
diminished perforin. Considering the fact that these patients had
similar mRNA expression of perforin, correct sorting of existing
perforin into lysosomes and the existence of mature perforin in
patient NK cells, perforin biosynthesis seems to be independent
of AP3 complex (75). Yet it remains possible that the AP3 com-
plex is involved in sorting of proteins critical for perforin stability
once perforin has made it into the lytic granule. This discrepancy
between CTLs and NK cells from these patients might be due to
further cell-type-specific roles of AP3 between NK cells and CTLs
since lytic granule biogenesis is known to be different between
these two cell types; lytic granules are preformed in resting NK
cells, whereas lytic granules are generated after activation in CTLs
(78–80). Clearly more patients need to be accumulated to better
understand these different observations. It is also interesting to
note that enlarged lytic granules were observed in CTLs of HPS2
patients (77). Further elucidation of the AP3 complex target pro-
teins required for lytic granule sorting as well as other potential
roles of the AP3 complex in the biogenesis of lytic granules will be
able to answer these questions.
Lastly, Clark et al. suggested that the AP3 complex might also
play a more direct role(s) in the cytotoxic process of CTLs. They
observed that lytic granules from AP3-deficient CTLs fail to cluster
around the microtubule-organizing center (MTOC) when con-
jugated with appropriate target cells (77). This seems to be due
to a failure of lytic granules to move along the microtubules or
an inability to attach to microtubules. In addition, it is not clear
whether this observed defect is a result of a direct role for AP3
in mediating lytic granule clustering at the MTOC, or due to
a sorting failure of a protein(s) critical for attachment and/or
movement of lytic granules along microtubules. Definitely, future
studies elucidating the mechanism resulting in the phenotypes of
AP3-deficiency in CTLs and NK cells will be very exciting.
Chediak–Higashi syndrome
Chediak–Higashi syndrome is another disease caused by defec-
tive lytic granule generation in NK cells and CTLs. The disease
is inherited in an autosomal recessive manner and the main clin-
ical symptoms of CHS are partial albinism and recurrent infec-
tions in the lung and skin. Mild coagulation defects and varying
degrees of neurologic dysfunctions are also commonly observed
in CHS patients. Although patients are often able to clear bacter-
ial infections with the help of antibiotics, they instead develop an
accelerated phase of hemophagocytic lymphohistiocytosis; seen
by infiltration of macrophages and lymphocytes into the major
organs of the body (81). Clinically, CHS and Griscelli syndromes
(GSs; discussed in later section) present with identical features.
However, at the cellular level, CHS can be distinguished from GS
by the fact that CHS cells contain abnormally enlarged lysosomes
and secretory lysosomes. Therefore, this cellular feature is used as
the key diagnostic criterion of CHS (82–84). In 1996, the respon-
sible gene for CHS was mapped to CHS1/LYST gene (beige gene in
the mouse model of CHS) (85, 86). The CHS1/LYST gene is highly
conserved in all species, and a unique region at the C-terminal end
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of the protein called the BEACH (Beige and Chediak) motif defines
a family of proteins homologous to the CHS1/LYST protein. Our
current understanding suggests that all BEACH family proteins
participate in vesicle trafficking (83, 87).
CHS1/LYST proteins are expressed at very low levels in all cell
types, and are involved in maintaining the morphology of lyso-
somes and secretory lysosomes (83). However, similar to HPS2,
only cells with secretory lysosome function are impaired (83, 88).
In fact, although few in number, giant lytic granules are observed
in NK cells and CTLs from CHS patients, and defects in cytotoxi-
city of both cell types have been reported from many studies (19,
21). In the case of NK cells from CHS patients, their numbers
are within normal range, but the absence of CHS1/LYST causes
defects in natural cytotoxicity as well as ADCC (89–95). NK cells
from CHS patients are able to efficiently bind target cells sug-
gesting that the defect in NK cell-mediated cytotoxicity is due
to problems in the actual cytotoxicity process. However, detailed
molecular roles of CHS1/LYST in NK cell-mediated cytotoxicity
have not been reported to date. Interestingly, treatment with inter-
ferons (IFNs) increase the cytotoxic capacity of NK cells from CHS
patients (92, 93, 96), suggesting that IFN signaling is able to rescue
cytotoxicity defects of CHS NK cells, at least partially.
Most of our knowledge regarding the cellular functions of
CHS1/LYST protein were obtained from studies of CTLs from
CHS patients. Unexpectedly, while giant lysosomal organelles were
observed in the patients’ cells, the biogenesis, processing, and
expression level of lytic proteins such as perforin and granzymes
were normal, as were their sorting into lytic granules after acti-
vation. However, as time went on, the lytic granules began to
fuse together becoming giant organelles (97, 98). Based on these
observations, it is likely that the CHS/LYST protein either pre-
vents abnormal fusion between lysosomal organelles or separates
lysosomal membranes after normal fusion events, thus regulat-
ing lysosomal size. Significantly, CTLs from CHS patients were
unable to secrete their granules in response to TCR ligation (97),
suggesting that the cytotoxicity defects observed in NK cells and
CTLs from CHS patients result from an exocytosis defect. Further
studies elucidating the roles of CHS1/LYST in lysosomal fusion
and exocytosis as well as the roles of other BEACH family pro-
teins will provide clearer insight into the NK and CTL phenotypes
observed in patients as well as the biogenesis of lytic granules and
melanosomes.
ADHESION OF NK CELLS TO TARGET CELLS
Natural killer cells rapidly accumulate at the site of inflamma-
tion through the stimulation of inflammatory chemokine recep-
tors and adhesion molecules expressed on their cell surface (1).
Although the roles of weak adhesion molecules like selectin fam-
ily members have not been directly examined in NK cell – target
cell binding, it is generally appreciated that the first step toward
the development of NK cell cytotoxicity is weak integrin-mediated
adhesion to target cells (99). Signals from this weak adhesion,along
with the initial signaling resulting from the engagement of activat-
ing/inhibitory receptors on the NK cell with corresponding ligands
on the target cell, determines whether the NK cell should detach
(strong inhibitory signal) or establish a firm adhesion (strong acti-
vation signals) leading to the formation of the cytotoxic synapse
(CS). Along with high affinity interactions toward their ligands,
integrins were also observed to cluster at the CS of NK cells,
strengthening adhesion (avidity) (100–102) and promoting the
scanning of target cells (Figure 1) (11, 12, 99). In addition to
being an important mediator of cell–cell adhesion, integrins can
serve as co-stimulatory molecules enhancing cytotoxicity signals
from other activating NK receptors (103–105), as well as promot-
ing lytic granule polarization following ligand engagement (104,
106–108).
LEUKOCYTE ADHESION DEFICIENCY TYPE I
Leukocyte adhesion deficiencies (LAD) are autosomal recessive
diseases caused by mutations in the genes encoding adhesion mol-
ecules or molecules critical for processing/activation of adhesion
molecules. Leukocyte adhesion deficiency type I (LAD-I) is the
most common type of LAD, and is caused by mutation in the gene
encoding the β2-subunit of the integrin (CD18), ITGB2 (Figure 1)
(109). A variety of mutations have been found in ITGB2, which can
impact the expression of CD18 as well as its ability to bind a ligand
(110). The main clinical symptoms of these patients are recurrent
bacterial and fungal infections in the skin and mucosa, absence
of pus formation at the infection sites, and impaired healing after
infection. An abnormally high number of leukocytes in the blood
are also a common feature of this disease, indicative of inefficient
recruitment to sites of inflammation (19, 110). Supporting the
essential role of integrins in mediating cytotoxicity signaling, NK
cells from LAD-I patients showed defective natural cytotoxicity as
well as ADCC compared to control NK cells (111–113). Although
the defective cytotoxicity of patients’ NK cells seems to be mainly
due to impaired adhesion to target cells, it was recently suggested
that LFA-1 (CD11a/CD18) might be required for clustering of
lytic granules to the MTOC after target cell binding (114). How-
ever, further studies are required to clearly conclude that impaired
lytic granule convergence observed in NK cells of LAD-1 patients
is due to the absence of LFA-1. It remains possible that the defect
observed in LAD-I NK cells might result from impaired/delayed
signaling from other NK receptors caused by defective adhesion
to target cells. One study suggested that the cytotoxicity defects
in LAD-I NK cells could be rescued at least partly via activation
with IL-2 (115). In this regard, it is very interesting to note that
activation of NK cells with only IL-2 treatment promoted cluster-
ing of lytic granules (114). How IL-2 signaling is able to rescue
cytotoxicity of NK cells (adhesion to target cells or clustering of
lytic granules) is unclear and will require further investigation.
LEUKOCYTE ADHESION DEFICIENCY TYPE III
Leukocyte adhesion deficiency type III (LAD-III) is caused by
mutation of the FERMT3 gene, which encodes Kindlin-3 (110).
Kindlin-3 is expressed only in cells of the hematopoietic lin-
eage (116), and like talin, regulates integrin-mediated adhesion
by binding directly to the integrin β-chain (Figure 1) (117, 118).
Patients with LAD-III have severe recurrent infections, leuko-
cytosis, and persistent bleeding (110). As expected from the
main role of Kindlin-3 in integrin-mediated adhesion, defective
integrin activation was observed in platelets, lymphocytes, and
polymorphonuclear leukocytes (PMNs) derived from LAD-III
patients (119–125). Recently, functions of NK cells from a single
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FIGURE 1 | Regulation of NK – target cell adhesion and generation
of F-actin at the cytotoxic synapse. Initial signals from the NK – target
interaction recruit multiple proteins responsible for integrin-mediated
adhesion and high affinity maturation as well as the accumulation of
F-actin at the cytotoxic synapse (CS). Absence of either the integrin
β2-subunit (CD18) or its regulator, Kindlin-3, results in leukocyte
adhesion deficiency type I or type III, respectively. NK cells from both
diseases present defective cytotoxicity due to failure of efficient target
binding and/or defective NK cell activation. The DOCK8–WASP complex
is also recruited to the NK-target interface, and a “DOCK8–CDC42–
WASP” pathway is likely responsible for F-actin reorganization, which
might facilitate integrin-mediated adhesion and provide the F-actin
meshwork critical for organization of the CS. Absence of either DOCK8
or WASP results in primary immunodeficiency disorders and NK cells
from these patients show impaired NK cytotoxic activity (see text for
details).
female infant patient were examined (126). Interestingly, specific
activating receptor-mediated cytotoxicity was defective, whereas
natural cytotoxicity mediated by multiple NK receptors was nor-
mal. It was suggested that Kindlin-3 might function by lowering
the signaling threshold required for NK cell activation. Clearly,
more patients will be needed to further define its role in NK cell-
mediated cytotoxicity. In addition, further insights into the cellular
roles of Kindlin-3 in inside-out/outside-in signaling by integrins
as well as elucidation of the relationship of Kindlin-3 and talin in
integrin regulation will be very helpful in understanding LAD-III.
ACTIN REORGANIZATION AT THE CYTOTOXIC SYNAPSE
Essential signaling molecules like NK activating/inhibitory recep-
tors are accumulated at the center of the interface known as the
central supramolecular activation cluster (cSMAC), whereas F-
actin and integrins are localized at the periphery of the interface
forming a ring-shaped peripheral supramolecular activation clus-
ter (pSMAC). Among these distinct molecular patterns at the
CS, F-actin accumulation at the pSMAC is thought to be one of
the early and critical events in NK cell-medicated cytotoxicity,
since clustering of NK receptors as well as adhesion molecules are
observed to be dependent on F-actin polymerization (13, 99, 101).
Two primary immunodeficiencies causing defective F-actin accu-
mulation at the CS of NK cells have provided some clues on how
F-actin accumulation might be regulated at the CS.
WISKOTT–ALDRICH SYNDROME
Wiskott–Aldrich syndrome (WAS) is an X-linked primary
immunodeficiency disorder characterized by recurrent infections,
prolonged bleeding, eczema, thrombocytopenia, and impaired cel-
lular and humoral immunity (127, 128). The disease is caused
by mutations of the WAS gene, which encodes the hematopoi-
etically expressed WAS protein (WASP) (129, 130). Depending
on the disease severity and type of mutation, WAS is further
subcategorized as X-linked thrombocytopenia (XLT) or X-linked
neutropenia (XLN) (127, 128). WASP is the founding member
of the WASP superfamily of F-actin nucleation promoting fac-
tors (NPFs), which stimulate the formation of branched F-actin
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via the ubiquitously expressed Arp2/3 complex (Figure 1) (131).
All members of the WASP superfamily contain a C-terminal
verprolin-connecting-acidic (VCA) domain that interacts with
profilin-G-actin and the Arp2/3 complex (127, 128, 132). WASP is
thought to play diverse roles in immune cells including formation
of the immunological synapse (IS), migration, and phagocyto-
sis (127, 128, 132). WASP-interacting protein (WIP; discussed
in the next section) constitutively stabilizes WASP in an auto-
inhibited conformation (133) in which the VCA domain is sta-
bilized through an interaction with the basic region (BR) and
CDC42/RAC GTPase binding domain (GBD). Cell stimulation
results in the cooperative interaction of the BR with phosphatidyli-
nositol (4,5)-biphosphate (PIP2) and active CDC42 (CDC42–
GTP) with the GBD, thereby leading to the release of the bound
VCA domain so that it can bind the Arp2/3 complex and promote
branched F-actin generation (134–138).
Wiskott–Aldrich syndrome protein was observed to localize at
the pSMAC of the CS along with F-actin in target-bound NK
cells, and the roles of WASP in NK cell-mediated cytotoxicity have
been examined using NK cells from WAS patients (101, 139, 140).
Although the proportion of NK cells in the blood was within the
normal range or higher in WAS patients, WAS NK cells showed
defective natural cytotoxicity as well as ADCC (139, 140). Impaired
cytotoxicity of WAS NK cells was due to inefficient conjugate for-
mation with target cells, a failure in F-actin accumulation at the
cell–cell contact site, clustering of integrins and CD2, and polar-
ization of lytic granules at the CS (Figure 1) (101, 139, 140).
Interestingly, ex vivo as well as in vivo treatment with IL-2 was
able to rescue impaired cytotoxicity of WAS NK cells (139, 141).
IL-2 treatment of WAS NK cells restored target binding efficiency,
F-actin accumulation, and polarization of lytic granules to the CS.
The IL-2-mediated rescue of the defect in WAS NK cells was found
to be independent of WASP function, but dependent on another
WASP family member, WAVE2 (141). These findings suggest that
there exists two distinct pathways for Arp2/3-generated F-actin
reorganization at the CS in NK cells, and future studies should
enable the use of IL-2 as a therapy to improve clinical symptoms
of WAS including severe herpes simplex virus (HSV) infection
caused by defective NK cell-mediated cytotoxicity.
Activation of NK cells by target cells or stimulation of CD16
was shown to activate CDC42 in NK cells (139), and accumulating
observations suggest that the spatiotemporal activation of CDC42
in NK cells is important in CS formation and cytotoxic activity
(142, 143). Therefore, based on current knowledge, NK cell acti-
vation results in the generation of active CDC42 at the CS, and
this leads to the activation of WASP. Activated WASP will then
contribute to F-actin reorganization at the CS, which will mediate
the clustering of CD2, integrins, and NK receptors. However, there
are still many important questions to be answered regarding the
role and regulation of WASP in NK cell-mediated cytotoxicity. For
example: (1) What are the upstream signaling pathways that lead
to the activation of CDC42 and the generation of PIP2 that are
required for WASP activation at the CS? (2) How is WASP accu-
mulated at the CS after the stimulation of NK cells? and (3) How
does WASP mediate the polarization of lytic granules toward the
CS? Future studies aimed at addressing these and other impor-
tant questions will provide insight into how WASP is regulated
and mechanistic insight into its role in the development of NK
cell-mediated killing.
WASP-INTERACTING PROTEIN DEFICIENCY
Deficiency of WASP-interacting protein was recently identified in a
female infant patient (144). The patient had a homozygous muta-
tion in the WIPF1 gene and both of her parents were heterozygous
for the same mutation, suggesting that the disease is inherited in
an autosomal recessive manner. WIP is ubiquitously expressed in
humans, although higher levels are observed in hematopoietic cells
(145). The clinical features were very similar to those observed in
WAS patients, including recurrent infections, thrombocytopenia,
eczema, and immunodeficiency. This is not surprising as WIP is
thought to maintain the stability of WASP and regulate WASP
activity (Figure 1) (145, 146). Consistent with this, WASP pro-
tein was not detected in the patient’s T cells, despite normal WAS
mRNA expression. However, several WASP-independent func-
tions of WIP have been observed in NK cells. First of all, WIP
was shown to be essential for formation of a multiprotein com-
plex composed of WIP, WASP, actin, and myosin IIA after NK cell
activation (147). WIP was also found to associate with the lytic
granules in NK cells and WIP-depleted NK cells failed to polarize
their lytic granules toward the CS (148). In addition, the expres-
sion level of major NK activating receptors (NKG2D, NKp30, and
NKp46) was lower on WIP-deficient NK cells compared to con-
trol NK cells. These findings also suggest that patients with WAS
symptoms cannot be simply diagnosed based on WASP expression
at the protein level, and will require sequence analysis of the WAS
and WIPF1 genes to distinguish between WAS and WIP deficiency.
DEDICATOR OF CYTOKINESIS 8 DEFICIENCY
Another PID that causes defective F-actin accumulation at the CS
of NK cells is the loss of dedicator of cytokinesis 8 (DOCK8).
DOCK8 is a member of the DOCK180 family of guanine
nucleotide exchange factors (GEFs) that mediate activation of
Rho family proteins and contribute to multiple cellular processes
including cell migration and phagocytosis (149–151). DOCK8
deficiency is a relatively recently identified primary combined
immunodeficiency that shows an autosomal recessive pattern of
inheritance (152, 153). The main clinical symptoms of these
patients are recurrent infections in the lung and skin, high IgE
levels in the serum, and severe allergies (152–154). The roles of
DOCK8 in human NK cells have been examined recently using
NK cells from DOCK8-deficient patients as well as primary human
NK cells and human NK cell-lines depleted of DOCK8 by RNAi
(155, 156). DOCK8-deficient/depleted NK cells showed defec-
tive natural cytotoxicity and specific activating receptor-mediated
NK cytotoxicity, suggesting that functional defects of NK cells in
DOCK8-deficient patients could be part of the cause for the fre-
quent sinopulmonary infections observed in these patients (152–
154,157). Defective accumulation of F-actin and clustering of inte-
grins at the IS were also observed in DOCK8-deficient/depleted
NK cells as well as B cells and CD8+ T cells from DOCK8-
mutant mice (155–158). Polarization of lytic granules toward
the CS was also defective in DOCK8-deficient/depleted NK cells
(155, 156). Mechanistically, DOCK8 was found to interact with
WASP and talin, and to mediate their localization to the CS of NK
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cells (Figure 1) (155). Significantly, DOCK8 was found to have
GEF-specificity toward CDC42 (155, 159). These findings pro-
vide an important link between the signaling pathways that might
activate WASP and may help explain the remarkable similarities
between WAS and DOCK8 deficiency. In fact both diseases share
many clinical symptoms [recurrent infections by certain types
of viruses, and high IgE levels] (127, 128, 132, 152–154, 157),
as well as phenotypes observed in NK cells [defective cytotoxic
activity, integrin-mediated adhesion, F-actin accumulation, and
polarization of lytic granules (101, 139, 140, 155, 156)].
Surprisingly, the addition of IL-2 was unable to rescue the cyto-
toxic defects seen in DOCK8-deficient NK cell suggesting that
DOCK8 is likely involved in the regulation of other signaling path-
ways in addition to its role in localizing and potentially activating
WASP. However, based on the current findings, it is very tempting
to hypothesize that DOCK8 mediates the recruitment of WASP
to the CS of NK cells after activation where it can generate active
CDC42 thus leading to the activation of WASP (Figure 1). Another
DOCK8-interacting partner, talin, associates with phosphatidyli-
nositol phosphate kinase type Iγ (PIPKIγ), which produces PtdIns
(4,5)P2 (PIP2), a molecule required for optimal activation of
WASP (134–138, 160–162). The activated WASP is then able to
interact with Arp2/3 inducing the generation of a branched F-
actin network,and this enhances the clustering of integrins and NK
receptors. Future studies testing the hypothesis of the “DOCK8–
CDC42–WASP” pathway should provide a clearer picture of the
formation of the CS. Lastly, one remaining question regarding the
role of DOCK8 and WASP is how they mediate the polarization
of lytic granules toward the CS. Based on current knowledge, it
is most likely that polarization of lytic granules toward the CS
occurs later than F-actin accumulation (101) since cytochalasin
D (Cyt D)-treated NK cells also showed defective polarization of
lytic granules (140). However, considering the fact that CDC42
is best known for regulating cellular polarity and is responsible
for MTOC polarization in T cells, macrophages, and dendritic
cells (DCs) (163–167), DOCK8 might regulate MTOC polariza-
tion through the activation of other CDC42 effector molecules
in addition to regulating the CDC42–WASP pathway leading to
F-actin accumulation.
POLARIZATION OF LYTIC GRANULES TOWARD CYTOTOXIC
SYNAPSE
Another important step required for NK cell-mediated cytotox-
icity is the polarization of lytic granules toward the CS. This
event occurs after the rearrangement of F-actin at the CS and
requires both F-actin polymerization and microtubule function,
since lytic granules fail to polarize toward the CS when either
F-actin accumulation or the microtubule network are disrupted
(101). As NK cells start to form conjugates with target cells, lytic
granules are rapidly clustered around the MTOC (Figure 2) (107).
This retrograde, minus-end-directed transport of lytic granules
on microtubules is Src kinase-dependent, and mediated by the
dynein/dynactin motor complex that constitutively associates with
lytic granules and tethers them to the microtubules (107, 114, 168).
In conjunction with the clustering of the lytic granules, the MTOC
polarizes toward the CS, thereby delivering the lethal cargo to the
site of target cell contact (101, 107, 168). Importantly, this process
occurs along with maturation of the CS, as it requires F-actin
accumulation, rearrangement of NK receptors, and clustering of
adhesion molecules.
Current knowledge suggests that activation of extracellular-
signal-regulated kinase (Erk), Vav1, and protein tyrosine kinase
2 (PYK2) are required for MTOC polarization in NK cells (169–
171). In addition to these molecules, several other proteins have
been identified that impact the polarization of lytic granules to
the CS (Figure 2). For example, interrupting the cellular function
of the CDC42-interacting protein-4 (CIP4) was shown to impair
MTOC polarization as well as NK cell-mediated cytotoxicity (172).
CIP4 was suggested to link the microtubule and F-actin network at
the CS through its ability to interact with microtubules and WASP.
In this regard, the scaffold protein IQGAP1 also has the potential to
interact with F-actin and microtubules, and silencing of IQGAP1
was also shown to impair NK cell cytotoxicity due to defective
MTOC polarization toward the CS (173). However, MTOC polar-
ization and cell-mediated killing were found to be normal in
mouse CTLs lacking IQGAP1 (174), highlighting again that dis-
tinct mechanisms regulating cell-mediated killing are engaged in
these two cell types. The Ral GTPase, RalA, also regulates MTOC
polarization toward the CS (175). Very recently, the small GTP-
binding protein,Arl8b, was found to interact with KIF5B, the heavy
chain of the microtubule plus-end-directed motor kinesin-1, and
mediate MTOC polarization in NK cells (176). How and where
the kinesin-1 motor is recruited to mediate movement of both the
MTOC and lytic granules toward the CS remains unclear. In CTLs,
a Rab27a/Slp3/kinesin-1 complex was reported to be critical for
final transport of polarized lytic granules along with microtubules
toward the CS (Figure 2). Interestingly, polarization of the MTOC
toward the CS was normal when kinesin-1 was interrupted in CTLs
(177). It will be interesting to analyze these seemingly different
roles of kinesin-1 in both NK cells and CTLs. Lastly, although not
examined in NK cells, activity of CDC42 might also be essential
for MTOC polarization considering similar roles in other immune
and non-immune cells (163–167).
Following the clustering of the lytic granules at the MTOC, the
MTOC docks near the plasma membrane (PM) facilitating fusion
of lytic granules into the secretory cleft formed between the NK
cell and target cell (168, 178). Previous studies using conventional
confocal microscopy suggested that the lytic granules pass through
an actin-cleared region at the center of the CS (101, 102); however,
recent approaches using super-resolution microscopy suggest that
the secretory region at the center of the CS is not totally absent of
F-actin. Instead, a hypodense branched F-actin meshwork exists
in the central region of the CS that is rearranged to produce small
pores through which the lytic granules travel (179, 180). The pre-
viously suggested role of myosin IIA, an actin motor protein, in
the final transit of lytic granules through the actin-rich region of
the CS are consistent with this new finding and will be discussed in
the next section (Figure 2). It still remains to be determined how
the F-actin network at the secretory region is regulated to allow
lytic granule movement by the myosin motor protein.
MYH9-RELATED DISEASE
Myosin IIA is an actin-based molecular motor that promotes
movement along F-actin and is known to be involved in numerous
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FIGURE 2 | Fusion and exocytosis of lytic granules during NK
cell-mediated cytotoxicity. Directed release of lytic granules toward
bound target cells is a multi-step process: (1) lytic granules are rapidly
clustered around the MTOC. This retrograde (minus-end-directed)
movement along the microtubules occurs rapidly and is mediated by the
dynein/dynactin motor complex. (2) The MTOC, along with accumulated
lytic granules, are polarized toward the CS, and several proteins have
been identified to be critical for this step. (3) Polarized lytic granules are
further delivered toward the CS along the microtubule (anterograde
transport) in a kinesin-1-dependent manner. (4) Myosin IIA facilitates the
final transit of the lytic granules through the hypodense F-actin
meshwork at the CS. NK cells from patients with MYH9-related diseases
fail to degranulate. (5) The final fusion of lytic granules with the plasma
membrane occurs in an orchestrated manner and requires multiple
molecules including Rab27a, its effector protein Munc13-4, SNARE
proteins, and their accessory proteins. Mutations in proteins involved in
this final fusion step have been found to cause immunodeficiency
disorders including Griscelli syndrome type 2, familial hemophagocytic
lymphohistiocytosis types 3, 4, and 5, all of which have similar clinical
symptoms, and defective lytic granule exocytosis.
cellular processes (181). Myosin IIA is a hexameric protein com-
posed of two heavy chains, two regulatory light chains, and two
essential light chains. The heavy chain of myosin IIA contains a
motor domain at the N-terminal head that binds to F-actin to per-
form its motor function through ATP hydrolysis, whereas the C-
terminal region performs filament formation, cargo binding, and
regulatory functions (182–184). In humans, mutations in MYH9
gene, which encodes the heavy chain, lead to autosomal dominant
diseases collectively known as MYH9-related diseases (MYH9-
RDs), which include May–Hegglin Anomaly, Sebastian Syndrome,
Fechtner Syndrome, and Epstein Syndromes (185, 186). The main
clinical features of MYH-RD are macrothrombocytopenia and
granulocyte inclusions.
Previous studies using the myosin light chain kinase inhibitor
ML-9 (1-[5-chloronaphthalene-1-sulfonyl]-1H -hexahydro-1,4-
diazepine) inhibited NK cell-mediated cytotoxicity (187), suggest-
ing that myosin IIA would be critical for NK cell effector activity.
Consistent with this notion, NK cells from MYH9-RD patients as
well as human NK cells that were either inhibited pharmacolog-
ically or depleted of myosin IIA function had impaired NK cell-
mediated cytotoxicity (188–190). Molecularly, it was found that
inhibition or depletion of myosin IIA did not affect the early steps
of NK cytotoxicity including target binding, F-actin accumulation,
or polarization of lytic granules, but caused impaired degranula-
tion (Figure 2). It was further found that a pool of myosin IIA
is associated constitutively with lytic granules, and facilitates the
final transit of the lytic granules through the F-actin meshwork at
the secretory region of the CS (190). It is important to note that
there might be other important roles of myosin IIA in NK cell-
mediated cytotoxicity. For example, as mentioned in the previous
section, it was shown that myosin IIA and actin are recruited to
WIP during NK cell activation (147). Lastly, a large fraction of
myosin IIA is found associated with the F-actin at the cell cortex,
suggesting that there are likely other functions of myosin IIA in
addition to its role in regulating lytic granule trafficking at the CS
(147, 188, 190). Future studies regarding other cellular roles of
myosin IIA in the NK cytotoxicity and their connection with roles
in lytic granule transport will be interesting.
FUSION OF LYTIC GRANULES WITH THE PLASMA
MEMBRANE
Exocytosis of lytic granules requires membrane fusion between
lytic granules and the PM. An increasing number of studies
suggest that small GTPases, including Rab–GTPases, known to
regulate membrane trafficking and fusion are important regula-
tors of lytic granule exocytosis in NK cells (191, 192). Following
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GDP to GTP exchange, these small GTPases are able to inter-
act with their effector proteins involved in protein sorting, motor
activity, and tethering, thereby impacting membrane trafficking.
Therefore, they are suggested to play important roles, at least in
determining specificity of the initial tethering step (Figure 2) (193,
194). In fact, mutation in Rab27a is known to be responsible for
a PID known as Griscelli syndrome type 2 (GS2), which will be
discussed in detail below (195, 196).
In addition to Rab proteins, the soluble N -ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) proteins,
which are known to mediate most membrane fusion events in
eukaryotic cells, also participate in exocytosis (197–199). There
are approximately 40 SNARE family proteins in humans with
different combinations of SNARE proteins expressed in differ-
ent cell types. In addition, each SNARE protein exhibits a distinct
localization pattern suggesting that selective pairings of SNARE
members in specific organelles (like lytic granules) constrain their
target binding (197–199). All SNARE proteins contain a coiled-
coil SNARE motif at the center, and are structurally categorized
as either an R-SNARE or Q-SNARE (further subclassified as Qa-,
Qb-, Qc-, or Qb,c-SNARE). Membrane fusion is induced when
an R-SNARE protein, such as those found on the lytic granule
membrane binds to its cognate Q-SNARE proteins expressed on
the PM (Figure 2). Bundling of four SNARE motifs (one from
the R-SNARE, and three motifs from two or three Q-SNAREs)
makes a stable SNARE complex, and the exerted mechanical force
pulls the two membranes closer to promote membrane fusion.
Interestingly, familial hemophagocytic lymphohistiocytosis type
4 (FHL4) is the result of a mutation in the gene encoding a
Qa-SNARE protein called syntaxin-11 (STX11) (200, 201). In
addition to the selectivity of SNARE proteins, accessory proteins
including SM (Sec1/Munc18-like), Munc13-like, and synapto-
tagmin associate with SNARE proteins to regulate membrane
fusion both temporally and spatially (197–199, 202). Mutations in
Munc13-4 and Munc18-2/syntaxin-binding protein 2 (STXBP2)
are responsible for familial hemophagocytic lymphohistiocytosis
type 3 (FHL3) and familial hemophagocytic lymphohistiocyto-
sis type 5 (FHL5), respectively (Figure 2) (203–205). Lastly, the
entry of extracellular Ca2+ is essential for lytic granule exocytosis
(206). Although PIDs regarding this category are not discussed
in this review (please refer to reviews (21, 207) for more details),
NK cells from patients deficient in either the ER calcium sen-
sor STIM1 or the PM calcium channel ORAI1 showed defective
cytotoxicity due to impaired exocytosis of lytic granules, although
polarization of lytic granules toward the CS was normal (206).
Significantly, Munc13 proteins and synaptotagmin proteins con-
tain two calcium-dependent phospholipid-binding C2 domains
and are known to regulate activity of the SNARE complex in a
Ca2+-regulated manner (197, 199, 202). Likewise, members of the
synaptotagmin-like protein (Slp) family also share C-terminal tan-
dem C2 domains. Slps were also shown to interact with activated
Rab27 (Rab27–GTP) via the Slp homology domain (SHD) and
participate in docking granules to the membrane (208). Unfor-
tunately, we still do not have a clear picture as to which of
these proteins are regulating the membrane fusion steps in NK
cell-mediated cytotoxicity. However, as discussed below, clues to
understanding this seemingly complicated and tightly regulated
mechanism of lytic granule docking and fusion have been uncov-
ered by functionally antagonizing these molecular pathways and
examining NK cells from PID patients deficient in these key
molecules.
GRISCELLI SYNDROME TYPE 2
Griscelli syndrome type 2 is an autosomal recessive human disease
caused by mutations in the RAB27A gene that encodes the small
GTPase Rab27a (195, 196). GS2 is clinically characterized by severe
immunodeficiency, an accelerated phase of HLH, partial albinism,
and distinctive silvery-grayish hair (209, 210). GS2 is distinguished
from other subtypes of GS (GS1: mutation in MYO5A encod-
ing myosin Va; GS3: mutation in MLPH encoding melanophilin)
from the fact that only GS2 is associated with the development
of hemophagocytosis (211). Since all three responsible proteins
for GS are required for distribution of melanins in melanocytes
(212), hypopigmentation due to defective melanosome function
is a common feature of all subtypes of GS. On the other hand,
the fact that cytotoxic lymphocytes only express Rab27a among
the three proteins explains why abnormal immune function is
only observed in GS2 (213). NK cells from GS2 patients showed
defective cytotoxicity which could be at least partially restored
by treatment of IL-2 (192, 214–217). In CTLs of GS2 patients as
well as Rab27a mutant Ashen mice, docking of lytic granules at
the PM and the subsequent degranulation process were impaired
(195, 204, 218, 219). Supporting the role of Rab27a observed
in CTLs, degranulation of activated NK cells from GS2 patients
was defective (192), and depletion of Rab27a in the human NK
cell-line, NKL, showed a decreased number of lytic granules at
the PM (Figure 2) (191). As discussed above, synaptotagmin-
like proteins 1–3 (Slp1–3), which are effectors of Rab27a, are
expressed in CTLs and involved in lytic granule exocytosis (177,
220, 221). Interestingly, it was recently found that Slp3 interacts
with the kinesin-1 motor protein. This is significant, as the motor
activity of kinesin-1 was suggested to deliver the slp3/Rab27a com-
plex toward the CS of CTLs (177). Lastly, while Rab27a is in
a distinct compartment from lytic granules in both resting NK
cells and CTLs (192, 222), when they are activated, Rab27a is
recruited to lytic granules. Whether Rab27a binding to Slp3 or
some other effector molecule mediates this recruitment remains
to be determined.
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 3
Familial hemophagocytic lymphohistiocytosis type 3 is caused by
mutation in UNC13D, which encodes Munc13-4 (204). Like other
types of FHL, FHL3 patients present with hyperactive CTLs and
macrophages in the peripheral blood. Patients usually have fever,
hepatosplenomegaly, defective coagulation, and features of hemo-
phagocytosis (204, 223, 224). Initial studies of Munc13-4 function
reported that Munc13-4 is highly expressed in hematopoietic cells
and involved in cytotoxicity of CTLs by mediating the exocytosis
of lytic granules (204). In line with this finding in CTLs, cytotoxic
activities (both natural cytotoxicity and ADCC) were defective
in NK cells from FHL3 patients, whereas levels of cytokines pro-
duced by activated NK cells were normal (48, 53, 225). Consistent
with the defect being at the level of lytic granule fusion, the
polarization of lytic granules toward the CS was normal, but
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the patient NK cells failed to degranulate (Figure 2) (53, 54).
As indicated above, Munc13-4 contains one diacylglycerol (DAG)
binding C1 domain and two Ca2+-binding C2 domains (204),
suggesting it regulates SNARE conformation in Ca2+-dependent
manner like other Munc13 members in a process called “priming,”
which guides incomplete SNARE components for full assembly.
However, it is still unclear which target SNARE proteins are reg-
ulated by Munc13-4 and how it acts mechanically during NK
cell degranulation. However, one of the interesting findings to
note is that Munc13-4 was found to be an effector of activated
Rab27a (Rab27a–GTP) (226, 227). When NK cells become acti-
vated, both proteins were found to associate with lytic granules,
and the recruitment of each protein was dependent on the other
(192). It is also very intriguing to note that the recruitment of
these proteins to lytic granules also requires myosin IIA, since
inhibition of myosin activity blocked their recruitment (192).
Clearly much more work is needed to delineate the mechanisms by
which Rab27a and Munc13-4 regulate lytic granule docking and
fusion.
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 4
Familial hemophagocytic lymphohistiocytosis type 4 is caused
by mutations in the gene that encodes the Qa-SNARE protein
STX11 (200, 201). STX11 is considered an atypical member of
the syntaxin family, since it lacks the hydrophobic transmem-
brane domain found in other syntaxin family members that is
involved in membrane binding (228). Instead, STX11 is able to
associate with membranes via a cysteine-rich region located at its
C-terminal end (229). NK cells from FHL4 patients or human
NK cells depleted of STX11 showed defects in both natural cyto-
toxicity and specific activating receptor-mediated cytotoxicity (54,
230). Polarization of lytic granules toward the CS was normal in
these NK cells, but they failed to degranulate suggesting the roles of
STX11 in the late step of lytic granule release (Figure 2). Recently
established STX11-deficient mice also support findings from the
patients (231, 232). Interestingly, the NK cell defects from FHL4
patients were partly rescued with IL-2 treatment (54). It is of inter-
est that STX11 localizes to the late endosome and the TGN (233,
234). Over-expressed STX11 also showed a distinct localization
pattern that was different from both Rab27a and perforin in rest-
ing NKLs, but upon activation, they colocalized with each other
at the CS. It is unclear why these proteins (Rab27a, Munc13-4,
and STX11) exist in distinct subcellular compartments prior to
activation, but one possible explanation would be the separation
of exocytic machineries and lytic granules in the resting state to
prevent premature granule exocytosis. Another important issue
remaining to be resolved is the identification of the other SNARE
complex members that contribute to membrane fusion. Two R-
SNARE proteins, VAMP4 and VAMP7, were recently shown to
colocalize with perforin in activated NK cells, and mediate lytic
granule exocytosis (235, 236). The Qb,c-SNARE protein, SNAP23,
is known to interact with STX11 in B cells; therefore, it is intrigu-
ing to hypothesize that it might also mediate degranulation of
lytic granules in NK cells in cooperation with STX11. STX11 was
also identified to interact with Munc18-2/STXBP2, which might
play important roles in priming the SNARE complex containing
STX11 (203, 205).
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 5
Familial hemophagocytic lymphohistiocytosis type 5 is a recently
identified type of FHL caused by mutation in STXBP2, which
encodes Munc18-2 (also called STXBP2) (203, 205). FHL5 patients
have either a very low level of Munc18-2 or no expression due
to homozygous or compound heterozygous mutations in the
STXBP2 gene. In addition to common clinical features of FHL,
some FHL5 patients additionally presented with colitis, bleeding
disorders, and hypogammaglobulinemia (210, 224). Munc18-2 is
a member of the SM (Sec1/Munc18-like) protein family, and likely
guides appropriate SNAREs for productive complex formation
(197–199, 202). Interestingly, Munc18-2 was found to colocal-
ize and interact with STX11 and the protein expression level of
STX11 seems to correlate with that of Munc18-2. However, the
absence of STX11 did not affect Munc18-2 protein levels suggest-
ing that Munc18-2 might be the main SM protein regulating the
STX11 SNARE complex (203). Importantly, NK cells from these
patients presented with impaired cytotoxic activity due to defec-
tive degranulation (Figure 2) (203, 205, 224, 237). Interestingly,
similar to what has been observed in NK cells from FHL4 patients,
IL-2 stimulation of NK cells from FHL5 patients partially rescued
the cytotoxicity defects, suggesting that the IL-2 pathway is able
to bypass the defective Munc18-2/STX11 pathway in both FHL4
and FHL5.
CONCLUSION
Advances in clinical diagnostics has substantially increased the
identification of patients with PIDs that affect NK cell numbers
or effector functions. In addition to furthering our understand-
ing of NK cells in the immune system (CKND and FKND), this
group of diseases has substantiated the important roles that NK
cells play in immune surveillance. Furthermore, the quantitative
and/or qualitative defects in NK cells derived from these patients
have highlighted essential molecular machineries shared among
immune cells and their importance in NK cell-mediated cyto-
toxicity. In fact, these loss-of-function mutations have provided
invaluable insight into the molecular processes regulating the
development of cell-mediated killing by NK cells. However, there
are many issues that still remain unanswered. First, how can IL-2-
mediated signaling pathways restore NK cell functions in multiple
PIDs? Secondly, what are the NK cell-specific mechanisms that
differentiate the cytotoxic processes engaged in NK cells from
those of CTLs (from biogenesis to exocytosis of lytic granules)?
Lastly, how do the signaling molecules that regulate the detailed
secretory pathway of lytic granules in NK cells cooperate with the
multiple tethering and fusion molecules to promote lytic granule
exocytosis? It is clear that PIDs have substantially impacted our
understanding of NK cell biology and the cellular mechanisms
that control the tightly regulated process of lytic granule release.
Further mechanistic insight into the process of NK cell-mediated
killing will hopefully reveal novel therapeutic approaches to treat
PID patients.
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